NCT06667141 is a Phase 1 clinical trial of ACR-2316 in Specific Advanced Solid Tumors, sponsored by Acrivon Therapeutics.

Who is sponsoring NCT06667141?

NCT06667141 is sponsored by Acrivon Therapeutics.

What drugs are being tested in NCT06667141?

Interventions in NCT06667141: ACR-2316.

What condition does NCT06667141 study?

NCT06667141 studies Specific Advanced Solid Tumors.

Is NCT06667141 still recruiting?

NCT06667141 is currently recruiting now. Last updated 23 March 2026.

Last reviewed 2026-03-23 · How we verify

NCT06667141

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Recruiting now Phase 1 Last updated 23 March 2026

What this trial tests

Phase 1 trial testing ACR-2316 in Specific Advanced Solid Tumors in 100 participants. Currently enrolling.

Timeline

8 October 2024

Primary endpoint
12 August 2026

12 December 2026

Quick facts

Lead sponsor	Acrivon Therapeutics
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	8 October 2024
Primary completion	12 August 2026
Estimated completion	12 December 2026
Sites	15 locations across United States

Drugs / interventions tested

ACR-2316 — full drug profile →

Conditions studied

Specific Advanced Solid Tumors — all drugs for Specific Advanced Solid Tumors →

Sponsor

Acrivon Therapeutics — full company profile →

Who can join

18 and older, any sex, with Specific Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

WEE1 inhibitors synergise with mRNA translation defects via activation of the kinase GCN2
Wilson JCJ, Zhu J, Lam S, Hart A, et al · · 2025 · cited 2× · DOI 10.1101/2025.03.12.642825
WEE1 inhibitors synergise with mRNA translation defects via activation of the kinase GCN2.
Wilson JCJ, Zhu J, Vinciauskaite V, Lloyd EG, et al · · 2025 · cited 1× · PMID 41068143 · DOI 10.1038/s41467-025-64050-5

Verify or expand the search:

Other Acrivon Therapeutics trials

Trials by the same sponsor.

NCT05548296 — A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06667141 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Acrivon Therapeutics
Last refreshed: 23 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06667141.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing